End-of-day quote
Korea S.E.
23:00:00 20/05/2024 BST
|
5-day change
|
1st Jan Change
|
2,005
KRW
|
+1.16%
|
|
+4.54%
|
-9.48%
|
05-03 |
WSI Co., Ltd. agreed to acquire 67% stake in Intro Biopharma Co., Ltd. from Synergy Innovation Co., Ltd., Seok-yong Park, Hyeong-geun Kim, Sejun Kim, Se-sil Kim and Highfly Co., Ltd. for KRW 18.8 billion.
|
CI
| 2023 |
WSI Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
|
CI
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
97,551
|
72,818
|
56,152
|
66,512
|
Enterprise Value (EV)
1 |
85,373
|
46,645
|
37,576
|
69,336
|
P/E ratio
|
-51.3
x
|
10.2
x
|
15.8
x
|
29.1
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.7
x
|
2.62
x
|
2.07
x
|
2.15
x
|
EV / Revenue
|
3.24
x
|
1.68
x
|
1.39
x
|
2.25
x
|
EV / EBITDA
|
14.5
x
|
7.35
x
|
9.13
x
|
17.4
x
|
EV / FCF
|
-82.3
x
|
5.69
x
|
-4.09
x
|
-3.02
x
|
FCF Yield
|
-1.22%
|
17.6%
|
-24.4%
|
-33.1%
|
Price to Book
|
4.04
x
|
2.19
x
|
1.49
x
|
1.65
x
|
Nbr of stocks (in thousands)
|
28,358
|
30,028
|
30,028
|
30,028
|
Reference price
2 |
3,440
|
2,425
|
1,870
|
2,215
|
Announcement Date
|
22/03/21
|
22/03/22
|
22/03/23
|
20/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
23,721
|
26,386
|
27,776
|
27,129
|
30,877
|
EBITDA
1 |
4,775
|
5,901
|
6,345
|
4,116
|
3,982
|
EBIT
1 |
4,560
|
5,624
|
6,007
|
3,684
|
3,343
|
Operating Margin
|
19.22%
|
21.31%
|
21.63%
|
13.58%
|
10.83%
|
Earnings before Tax (EBT)
1 |
4,616
|
-488
|
9,281
|
5,592
|
3,595
|
Net income
1 |
3,527
|
-1,640
|
7,175
|
4,368
|
2,877
|
Net margin
|
14.87%
|
-6.22%
|
25.83%
|
16.1%
|
9.32%
|
EPS
2 |
152.0
|
-67.00
|
237.7
|
118.1
|
76.24
|
Free Cash Flow
1 |
908.2
|
-1,038
|
8,202
|
-9,180
|
-22,980
|
FCF margin
|
3.83%
|
-3.93%
|
29.53%
|
-33.84%
|
-74.42%
|
FCF Conversion (EBITDA)
|
19.02%
|
-
|
129.25%
|
-
|
-
|
FCF Conversion (Net income)
|
25.75%
|
-
|
114.31%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/03/21
|
22/03/21
|
22/03/22
|
22/03/23
|
20/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
2,824
|
Net Cash position
1 |
3,867
|
12,178
|
26,172
|
18,577
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
0.7092
x
|
Free Cash Flow
1 |
908
|
-1,038
|
8,202
|
-9,180
|
-22,980
|
ROE (net income / shareholders' equity)
|
37.1%
|
-8.81%
|
24.6%
|
12.1%
|
7.21%
|
ROA (Net income/ Total Assets)
|
19.8%
|
15.3%
|
9.25%
|
4.19%
|
3.54%
|
Assets
1 |
17,808
|
-10,732
|
77,591
|
104,204
|
81,239
|
Book Value Per Share
2 |
2,854
|
851.0
|
1,105
|
1,259
|
1,339
|
Cash Flow per Share
2 |
964.0
|
162.0
|
830.0
|
450.0
|
214.0
|
Capex
1 |
65.3
|
481
|
3,059
|
10,352
|
20,730
|
Capex / Sales
|
0.28%
|
1.82%
|
11.01%
|
38.16%
|
67.14%
|
Announcement Date
|
22/03/21
|
22/03/21
|
22/03/22
|
22/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -9.48% | 43.76M | | +20.12% | 73.31B | | -4.60% | 23.98B | | +4.89% | 8.8B | | +9.21% | 8.6B | | -20.79% | 8.07B | | -1.41% | 4.16B | | +12.27% | 4.14B | | -2.75% | 3.88B | | +23.24% | 3.72B |
Pharmaceuticals Wholesale
|